Cargando…
Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View
OBJECTIVES: Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of vascular malformations with an absence of capillaries between arteries and veins. One major manifestation site is the nasal mucous membrane where recurrent nosebleeds occur. Our clinical strategy to treat pat...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Otorhinolaryngology-Head and Neck Surgery
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426390/ https://www.ncbi.nlm.nih.gov/pubmed/27440131 http://dx.doi.org/10.21053/ceo.2016.00318 |
_version_ | 1783235465779871744 |
---|---|
author | Wirsching, Kornelia E. C. Kühnel, Thomas S. |
author_facet | Wirsching, Kornelia E. C. Kühnel, Thomas S. |
author_sort | Wirsching, Kornelia E. C. |
collection | PubMed |
description | OBJECTIVES: Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of vascular malformations with an absence of capillaries between arteries and veins. One major manifestation site is the nasal mucous membrane where recurrent nosebleeds occur. Our clinical strategy to treat patients with HHT has the aim to reduce nasal bleeding long-term with minimal local and general side effects. METHODS: We describe staged diagnosis and therapy including individual medical treatments of 97 patients with HHT. The success of treatment is monitored with a systematic questionnaire. RESULTS: The neodymium-doped yttrium aluminium garnet (Nd:YAG) laser therapy remains standard treatment of choice with no major side effects despite the need for repeated treatment. In addition new treatment strategies like nasal occlusion, local drug therapy, and nasal septal splinting show initial success. CONCLUSION: Improvement of the quality of life of HHT patients can be achieved by a multimodal concept. Several new treatment strategies like nasal septal splinting and nasal occlusion successfully expand the range of established methods. Further studies have to prove the safety and long-term effectiveness of the described individual medical treatments. |
format | Online Article Text |
id | pubmed-5426390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Korean Society of Otorhinolaryngology-Head and Neck Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-54263902017-06-01 Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View Wirsching, Kornelia E. C. Kühnel, Thomas S. Clin Exp Otorhinolaryngol Original Article OBJECTIVES: Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of vascular malformations with an absence of capillaries between arteries and veins. One major manifestation site is the nasal mucous membrane where recurrent nosebleeds occur. Our clinical strategy to treat patients with HHT has the aim to reduce nasal bleeding long-term with minimal local and general side effects. METHODS: We describe staged diagnosis and therapy including individual medical treatments of 97 patients with HHT. The success of treatment is monitored with a systematic questionnaire. RESULTS: The neodymium-doped yttrium aluminium garnet (Nd:YAG) laser therapy remains standard treatment of choice with no major side effects despite the need for repeated treatment. In addition new treatment strategies like nasal occlusion, local drug therapy, and nasal septal splinting show initial success. CONCLUSION: Improvement of the quality of life of HHT patients can be achieved by a multimodal concept. Several new treatment strategies like nasal septal splinting and nasal occlusion successfully expand the range of established methods. Further studies have to prove the safety and long-term effectiveness of the described individual medical treatments. Korean Society of Otorhinolaryngology-Head and Neck Surgery 2017-06 2016-07-21 /pmc/articles/PMC5426390/ /pubmed/27440131 http://dx.doi.org/10.21053/ceo.2016.00318 Text en Copyright © 2017 by Korean Society of Otorhinolaryngology-Head and Neck Surgery This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Wirsching, Kornelia E. C. Kühnel, Thomas S. Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View |
title | Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point
of View |
title_full | Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point
of View |
title_fullStr | Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point
of View |
title_full_unstemmed | Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point
of View |
title_short | Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point
of View |
title_sort | update on clinical strategies in hereditary hemorrhagic telangiectasia from an ent point
of view |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426390/ https://www.ncbi.nlm.nih.gov/pubmed/27440131 http://dx.doi.org/10.21053/ceo.2016.00318 |
work_keys_str_mv | AT wirschingkorneliaec updateonclinicalstrategiesinhereditaryhemorrhagictelangiectasiafromanentpointofview AT kuhnelthomass updateonclinicalstrategiesinhereditaryhemorrhagictelangiectasiafromanentpointofview |